Accessing Pharma Assets: Having the Right People Helps
This article was originally published in Start Up
Executive Summary
Out-licensing will never be a top priority for pharmaceutical firms. But where a biotech has insider knowledge of a particular program or group of programs within the larger firm, out-licensing is happening--sometimes without any clawbacks at all. This activity's helping create biotechs, and also helping them leap closer to market with nearly-approved drugs.
You may also be interested in...
Syndax Leverages Novel IP for Cash, Phase II HDAC
Syndax has parlayed its HDAC/nuclear receptor ligand combo IP into a $40 million Series A backed by Domain and MPM and a licensing deal with Bayer-Schering.
Syndax Leverages Novel IP for Cash, Phase II HDAC
Syndax has parlayed its HDAC/nuclear receptor ligand combo IP into a $40 million Series A backed by Domain and MPM and a licensing deal with Bayer-Schering.
Synosis: the Financial Leverage of Translational Medicine
Biotech investors have struggled with the fact that it takes take years, hundreds of millions of dollars, and widely varying sets of expertise to create a product. For Synosis, the answer is translational medicine: it starts life with nine compounds from three European companies, aiming to figure out the best indications and dosing for each, prove them through Phase II, and then out-license them.